In this study, researchers utilized an AAVrh10 vector to deliver a computationally-designed, thermostable form of GCase (dGCase) directly into the left lateral ventricle of Gba−/−;Gbatg mice, a model for type 3 GD. The results demonstrated significant improvements in the treated mice, including increased body weight, extended lifespan, and enhanced motor function compared to mice receiving the wild-type GCase (wtGCase) via the same vector.
Biochemical analyses revealed a reduction in GlcCer levels and an increase in GCase activity in the brain’s right hemisphere of dGCase-treated mice. Additionally, these mice exhibited reduced neuroinflammation and lower expression of genes typically elevated in neurological forms of GD. These findings suggest that modified enzymes, when delivered using an optimized AAV vector, may offer a more effective therapeutic approach for lysosomal storage diseases and potentially other monogenetic disorders.
This study underscores the potential of AAV vector construction and protein engineering in developing more effective treatments for genetic diseases, particularly those with neurological involvement.
https://www.nature.com/articles/s41434-024-00476-8
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Ultragenyx Provides Update on Stage 1 Cohorts in Phase 1/2/3 Cyprus2+ Study for Wilson Disease with AAV9 Gene Therapy
October 3, 2024 NOVATO, Calif. — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced promising results from the ongoing Phase 1/2/3 Cyprus2+ study evaluating UX701 gene therapy for Wilson disease. Early-stage data from Stage 1 of the trial revealed significant...
World-First CAR-T Therapy Using Donor Cells Sends Autoimmune Diseases into Remission
In a groundbreaking advancement, three individuals suffering from severe autoimmune diseases have achieved remission after receiving a revolutionary therapy using donor-derived immune cells. This pioneering treatment, which utilized bioengineered immune cells known as...
Novel gene therapy shows promise in targeting a mutation linked to epilepsy
Clearance of mutant protein & restoration of normal neuronal activity by Gapmer ASO. Credit: NUS MedicineResearchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) are working on a therapy that holds potential in treating...
Purespring nabs $105M to take gene therapy into the clinic as IgAN field matures
Purespring Therapeutics has reeled in £80 million ($105 million) to test two gene therapies in humans. The Sofinnova Partners-led Series B, disclosed Wednesday morning, will carry the London startup into an open-label Phase 1/2 next year for a kidney disease that has...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
